TY - JOUR AU - Drew, B. J. AU - Ackerman, M. J. AU - Funk, M. AU - Gibler, W. B. AU - Kligfield, P. AU - Menon, V. PY - 2010 DA - 2010// TI - Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation JO - Circulation. VL - 121 UR - https://doi.org/10.1161/CIRCULATIONAHA.109.192704 DO - 10.1161/CIRCULATIONAHA.109.192704 ID - Drew2010 ER - TY - JOUR AU - Roden, D. M. PY - 2019 DA - 2019// TI - A current understanding of drug-induced QT prolongation and its implications for anticancer therapy JO - Cardiovasc Res VL - 115 UR - https://doi.org/10.1093/cvr/cvz013 DO - 10.1093/cvr/cvz013 ID - Roden2019 ER - TY - JOUR AU - Janne, P. A. AU - Yang, J. C. AU - Kim, D. W. AU - Planchard, D. AU - Ohe, Y. AU - Ramalingam, S. S. PY - 2015 DA - 2015// TI - AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411817 DO - 10.1056/NEJMoa1411817 ID - Janne2015 ER - TY - JOUR AU - Soria, J. C. AU - Ohe, Y. AU - Vansteenkiste, J. AU - Reungwetwattana, T. AU - Chewaskulyong, B. AU - Lee, K. H. PY - 2018 DA - 2018// TI - Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1713137 DO - 10.1056/NEJMoa1713137 ID - Soria2018 ER - TY - JOUR AU - Yang, J. C. AU - Ahn, M. J. AU - Kim, D. W. AU - Ramalingam, S. S. AU - Sequist, L. V. AU - Su, W. C. PY - 2017 DA - 2017// TI - Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.3223 DO - 10.1200/JCO.2016.70.3223 ID - Yang2017 ER - TY - JOUR AU - Goss, G. AU - Tsai, C. M. AU - Shepherd, F. A. AU - Bazhenova, L. AU - Lee, J. S. AU - Chang, G. C. PY - 2016 DA - 2016// TI - Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30508-3 DO - 10.1016/S1470-2045(16)30508-3 ID - Goss2016 ER - TY - JOUR AU - Colclough, N. AU - Chen, K. AU - Johnstrom, P. AU - Friden, M. AU - McGinnity, D. F. PY - 2019 DA - 2019// TI - Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery JO - Drug Discov Today VL - 24 UR - https://doi.org/10.1016/j.drudis.2019.01.015 DO - 10.1016/j.drudis.2019.01.015 ID - Colclough2019 ER - TY - JOUR AU - Shah, R. R. AU - Shah, D. R. PY - 2019 DA - 2019// TI - Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology JO - Drug Saf VL - 42 UR - https://doi.org/10.1007/s40264-018-0772-x DO - 10.1007/s40264-018-0772-x ID - Shah2019 ER - TY - JOUR AU - Sebille, Y. Z. AU - Gibson, R. J. AU - Wardill, H. R. AU - Bowen, J. M. PY - 2015 DA - 2015// TI - ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis JO - Cancer Treat Rev VL - 41 UR - https://doi.org/10.1016/j.ctrv.2015.05.011 DO - 10.1016/j.ctrv.2015.05.011 ID - Sebille2015 ER - TY - JOUR AU - Tejpar, S. AU - Piessevaux, H. AU - Claes, K. AU - Piront, P. AU - Hoenderop, J. G. AU - Verslype, C. PY - 2007 DA - 2007// TI - Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study JO - Lancet Oncol VL - 8 UR - https://doi.org/10.1016/S1470-2045(07)70108-0 DO - 10.1016/S1470-2045(07)70108-0 ID - Tejpar2007 ER - TY - JOUR AU - Shah, R. R. AU - Morganroth, J. AU - Shah, D. R. PY - 2013 DA - 2013// TI - Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval) JO - Drug Saf VL - 36 UR - https://doi.org/10.1007/s40264-013-0047-5 DO - 10.1007/s40264-013-0047-5 ID - Shah2013 ER - TY - JOUR AU - Hasinoff, B. B. PY - 2010 DA - 2010// TI - The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity JO - Toxicol Appl Pharmacol VL - 244 UR - https://doi.org/10.1016/j.taap.2009.12.032 DO - 10.1016/j.taap.2009.12.032 ID - Hasinoff2010 ER - TY - JOUR AU - Khan, F. AU - Ismail, M. AU - Khan, Q. AU - Ali, Z. PY - 2018 DA - 2018// TI - Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review JO - Expert Opin Drug Saf VL - 17 UR - https://doi.org/10.1080/14740338.2018.1520837 DO - 10.1080/14740338.2018.1520837 ID - Khan2018 ER - TY - JOUR AU - Lapi, F. AU - Wilchesky, M. AU - Kezouh, A. AU - Benisty, J. I. AU - Ernst, P. AU - Suissa, S. PY - 2012 DA - 2012// TI - Fluoroquinolones and the risk of serious arrhythmia: a population-based study JO - Clin Infect Dis VL - 55 UR - https://doi.org/10.1093/cid/cis664 DO - 10.1093/cid/cis664 ID - Lapi2012 ER - TY - JOUR AU - Chen, X. AU - Cass, J. D. AU - Bradley, J. A. AU - Dahm, C. M. AU - Sun, Z. AU - Kadyszewski, E. PY - 2005 DA - 2005// TI - QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome JO - Br J Pharmacol VL - 146 UR - https://doi.org/10.1038/sj.bjp.0706389 DO - 10.1038/sj.bjp.0706389 ID - Chen2005 ER - TY - JOUR AU - Cardoso, T. AU - Almeida, M. AU - Friedman, N. D. AU - Aragao, I. AU - Costa-Pereira, A. AU - Sarmento, A. E. PY - 2014 DA - 2014// TI - Classification of healthcare-associated infection: a systematic review 10 years after the first proposal JO - BMC Med VL - 12 UR - https://doi.org/10.1186/1741-7015-12-40 DO - 10.1186/1741-7015-12-40 ID - Cardoso2014 ER -